Krystal Biotech
KRYS
90 hedge funds and large institutions have $635M invested in Krystal Biotech in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 31 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
62% more capital invested
Capital invested by funds: $393M → $635M (+$243M)
6% more funds holding
Funds holding: 85 → 90 (+5)
1.17% more ownership
Funds ownership: 65% → 66.17% (+1.2%)
0% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 31
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$19.3M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$10.4M |
| 3 |
Goldman Sachs
New York
|
+$3.92M |
| 4 |
Citigroup
New York
|
+$2.3M |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$5.79M |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$4.17M |
| 3 |
AG
Artal Group
Luxembourg
|
-$3.43M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.7M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.21M |
KRYS Hedge Fund Activity: Q4 2019 in Review
90 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2019, worth a combined $635M — up 62% from $393M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new KRYS positions and 6 closed out — a net gain of 6 holders — while 31 added to existing stakes and 31 trimmed.
The largest buyer was OrbiMed, adding an estimated $19.3M. The largest seller was VOYA Investment Management, cutting an estimated $5.79M.
- 90 institutional investors held Krystal Biotech (KRYS) as of Q4 2019, up from 85 in Q3 2019.
- Funds reported $635M of Krystal Biotech stock for Q4 2019, up 62% quarter-over-quarter.
- 12 funds opened new Krystal Biotech positions in Q4 2019 and 6 closed out, a net change of +6 holders.
- The largest Krystal Biotech buyer in Q4 2019 was OrbiMed, an estimated $19.3M added.
- The largest Krystal Biotech seller in Q4 2019 was VOYA Investment Management, an estimated $5.79M sold.
Based on aggregated 13F filings for Q4 2019.